Your Article Summary
See Latest ArticlesZila Enters into Merger Agreement with Tolmar
Zila, 06/26/09
Zila, Inc. announced that it has entered into a definitive merger agreement with Tolmar Holding, Inc., a privately held, pharmaceutical research, development, manufacturing and commercial operations company. Under terms of the agreement, Tolmar will acquire all of the outstanding shares of Zila for a cash purchase price of $0.38 per share, representing an approximate premium of 18% over the closing price of Zila's shares on June 2009. Total consideration paid by Tolmar includes the purchase of Zila's existing $12 million senior secured convertible debt at a discount.
Today in M&A/Partnerships...keeping you current
Receive free subspecialty "5-minute updates" via email
GSK completes extension of strategic collaboration with Aspen
GlaxoSmithKline, 12/02/09
Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility
Novartis, 11/25/09
Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
Gilead, 11/25/09